Apo-Timop

• Antihypertensive Agents
• Anti-Arrhythmia Agents
• Adrenergic beta-Antagonists
• ATC:C07AA06
• ATC:S01ED01

• Apo-Timol
• Apo-Timop
• Aquanil
• Betim
• Betimol
• Blocadren
• Istalol
• Novo-Timol
• Proflax
• Temserin
• Tenopt
• Tim-AK
• Timacar
• Timacor
• Timololum [INN-Latin]
• Timopic
• Timoptic
• Timoptic in Ocudose
• Timoptic-XE
• Timoptol

Combigan (Brimonidine Tartrate + Timolol Maleate)

Cosopt -(2%/0.5% Oph Dps) (Dorzolamide Hydrochloride + Timolol Maleate)

Timolide Tab (Hydrochlorothiazide + Timolol Maleate)

Timpilo 2 (Pilocarpine Hydrochloride + Timolol Maleate)

Timpilo 4 (Pilocarpine Hydrochloride + Timolol Maleate)

Xalacom (Latanoprost + Timolol Maleate)

C₁₃H₂₄N₄O₃S

http://www.rxlist.com/cgi/generic3/timololgfs.htm

Apo-Timop FDA

Apo-Timop MSDS

Wasson et al., J. Med. Chem. 15, 615 (1972)

316.421 g/mol

201.5-202.5 ^oC

2,74 mg / mL

Solid

1.761

Gotas, líquidos, soluciones, la solución (de acción prolongada); Tablet

En su forma oral que se utiliza para tratar la presión arterial alta y prevenir ataques al corazón, y de vez en cuando para prevenir las migrañas. En su forma oftálmica se usa para el tratamiento de ángulo abierto y glaucoma secundario de vez en cuando.

Similar al propranolol y el nadolol, timolol es un no-selectiva, beta-antagonistas de los receptores adrenérgicos. Timolol no tiene significativa simpaticomimética intrínseca, depresora directa del miocardio o local anestesia (estabilizadora de membrana) la actividad, pero posee un alto grado de solubilidad en lípidos. Timolol, cuando se aplica tópicamente en el ojo, tiene la acción de reducir la elevada, así como la normal, , La presión intraocular, acompañada o no por el glaucoma. La presión intraocular elevada es un factor de riesgo importante en la patogénesis de la pérdida glaucomatosa del campo visual y daño al nervio óptico.

La biodisponibilidad es alrededor del 60%

DL50 = 1190 mg / kg (oral, ratón), LD50 = 900 mg / kg (oral, rata). Los síntomas de sobredosis incluyen somnolencia, vértigo, dolor de cabeza, y el bloque atriventricular.

Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly, could become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g.,trauma or infection), they should immediately seek their physicianís advice concerning the continued use of the present multidose container. Patients should be instructed to invert the closed container and shake once before each use. It is not necessary to shake the container more than once. Patients requiring concomitant topical ophthalmic medications should be instructed to administer these at least 10 minutes before instilling Timolol GFS. Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. Transient blurred vision or visual disturbance, generally lasting from 30 seconds to 5 minutes, following instillation may impair the ability to perform hazardous tasks such as operating machinery or driving a motor vehicle.

Humanos y otros mamíferos